Watch on demand: Preventative migraine therapy in Australia: defining the role of CGRP therapy


9 Jun 2021

The first PBS listing of a CGRP inhibitor for migraine prevention is a game-changer for a condition with a huge health and economic burden in Australia. Last night a panel of experts discussed the pathophysiology of CGRP and headache, the development of CGRP targeting drugs and the practical applications of the treatments currently available.

Watch the discussion now:

Hosted by:

Doctor Bronwyn Jenkins, Neurologist, Honorary Medical Officer at Royal North Shore Hospital, President-elect for the Australian and New Zealand Headache Society (ANZHS), member of the Asian Regional Consortium for Headache (ARCH) and recent board member of the International Headache Society

With specials guests:

Professor Peter J. Goadsby,  Professor of Neurology at King’s College London and University of California, Los Angeles.

Doctor Calvin Chan, Neurologist, Department of Neurology, Palmerston North Hospital, Palmerston North, NZ.

Associate Professor Richard Stark, Consultant Neurologist, Alfred Health and Department of Neuroscience, Monash University, Melbourne.

This webinar is created independently by the limbic. Thank you to Eli Lilly Australia Pty Ltd for providing the non-restrictive educational grant that made it possible.

Already a member?

Login to keep reading.

Email me a login link